In the study with pharmacological DUSP6 inhibition, OVCAR8 and SKOV3 ovarian cancer cells showed greater sensitivity to carboplatin and paclitaxel in combination with BCI than to the drug alone. This evidence concerns the gene DUSP6 and ovarian carcinoma.